SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2002 (March 6, 2002)
-------------------------------
Introgen Therapeutics, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-21291 74-2704230
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
301 Congress Avenue, Suite 1850, Austin, Texas 78701
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (512) 708-9310
-----------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
(a)(i) On March 6, 2002, Introgen Therapeutics, Inc. (the "Company")
decided to cease its client-auditor relationship with Arthur Andersen LLP,
effective upon completion of Arthur Andersen LLP's services in connection with
the filing of the Company's Annual Report on Form 10-K for the six-month
transition period ended December 31, 2001.
(ii) Arthur Andersen LLP's reports on the Company's financial
statements for each of the years ended June 30, 2000 and 2001 did not contain an
adverse opinion or a disclaimer of opinion, and were not qualified or modified
as to uncertainty, audit scope, or accounting principles.
(iii) The decision to change independent public accountants was
recommended by the Audit Committee of the Company's Board of Directors and was
approved by the Company's Board of Directors.
(iv) During each of the two years ended June 30, 2000 and 2001, there
were no disagreements with Arthur Andersen LLP on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedures, which disagreements, if not resolved to the satisfaction of Arthur
Andersen LLP, would have caused it to make reference to the subject matter of
the disagreement in connection with its report.
(v) During each of the two years ended June 30, 2000 and 2001,
Arthur Andersen LLP did not advise the Company of any "reportable events" as
described in Item 304(a)(1)(v) of Regulation S-K under the Securities Act of
1933, as amended.
(b)(i) On March 6, 2002, the Company engaged Ernst & Young LLP ("E&Y")
as its principal accountant to audit the Company's financial statements.
(ii) During each of the two years ended June 30, 2000 and 2001 and
for the six-month interim period ended December 31, 2001, the Company did not
consult E&Y on any matters described in Item 304(a)(2)(i) of Regulation S-K.
(iii) During each of the two years ended June 30, 2000 and 2001
and for the six-month interim period ended December 31, 2001, the Company did
not consult E&Y on any matters described in Item 304(a)(2)(ii) of Regulation
S-K.
(c) The Company requested Arthur Andersen LLP to furnish a letter
addressed to the Commission, stating whether it agrees with the statements made
by the Company herein and, if not, stating the respects in which it does not
agree. A copy of this letter, dated as of March 12, 2002, is filed as Exhibit
16.1 to this Form 8-K.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
16.1 Letter re: Change in Certifying Accountant
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 12, 2002 INTROGEN THERAPEUTICS, INC.
/s/ James W. Albrecht, Jr.
------------------------------------
James W. Albrecht, Jr.
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
16.1 Letter re: Change in Certifying Accountant